Immunogenicity influences safety and efficacy of biologic drugs, with consequences ranging up to life-threatening reactions. Celerion has over 30 years’ experience in immunogenicity assessment using various immunoanalytical and cell-based technologies, one of the pioneers of immunogenicity testing from the mid-1990s.
Anti-drug antibody Assays (ADA) are critical to understanding drug immunogenicity as these parameters ultimately impact patients receiving biologics products. This approach ensures all parameters are evaluated.
Immunogenicity platforms are varied and plentiful, but possess a spectrum of advantages all driven by the particular biologic’s unique characteristics and development needs. The Celerion ScienceTM Team creates immunogenicity strategies across the drug development lifecyle in a customized, adaptive manner.
The range of immunogenicity needs is broad but our scientists customize the program specifically tailored to the compound and across species such as rodents, humans, and non-human primates.
Celerion 2026. All Rights Reserved. Privacy & Legal
Download PDF